To hear about similar clinical trials, please enter your email below
Trial Title:
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
NCT ID:
NCT05669105
Condition:
Non Small Cell Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords:
lung cancer
NSCLC
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Specimen sample
Description:
Participants will have up to 100 mL of whole blood collected.
Summary:
The study objective is to collect biospecimen samples (e.g., whole blood) from
participants diagnosed with active lung cancer to investigate the immune response to
develop treatments and therapies.
Criteria for eligibility:
Study pop:
The study will enroll up to 200 participants. Recruitment will occur through Sanguine
advertisements, partnerships with cancer foundations, and cancer centers. Participants
may be contacted for future studies.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Participants willing and able to provide written informed consent
- Participants are willing and able to provide appropriate photo identification
- Participant's age 18 - 100 years old
- Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or
Squamous Cell only. All stages are acceptable.)
- Participants must have associated tissue biomarker data (EFGR and MET mutations) in
their medical records
Exclusion Criteria:
- Participants who are pregnant or nursing
- Participants with a known history of HIV, hepatitis, or other infectious diseases
- Participants who have taken an investigational product in the last 30 days
- Participants who have experienced excess blood loss, including blood donation
defined as 250 mL in the last month or 500 mL in the previous two months
- Participants currently enrolled in a clinical trial
- Participants currently in remission
Gender:
All
Minimum age:
18 Years
Maximum age:
100 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sanguine Biosciences
Address:
City:
Waltham
Zip:
02451
Country:
United States
Status:
Recruiting
Contact:
Last name:
Thomas Goslin
Phone:
818-583-8844
Email:
tgoslin@sanguinebio.com
Investigator:
Last name:
Houman Hemmati, MD
Email:
Principal Investigator
Start date:
February 19, 2022
Completion date:
March 31, 2024
Lead sponsor:
Agency:
Sanguine Biosciences
Agency class:
Industry
Source:
Sanguine Biosciences
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05669105
